Shanna Miranti
Medical · Naples, FLNPI 1265408025
Payments from drug & device makers
Across 1,218 payments — averaging $340.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$125K
- Galderma Laboratories, L.p.$71K
- Organon$44K
- Ortho Dermatologics, A Division Of Bausch Health US, LLC$33K
- Arcutis Biotherapeutics, Inc.$30K
- Verrica Pharmaceuticals Inc.$27K
- plus $86K from 30 others
What the payments were for
- Consulting fees$78,49819%
- Speaking & faculty fees$244,44059%
- Travel & lodging$59,46414%
- Food & beverage$32,1478%
- Education$1550%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 254 | $124,938 |
| Galderma Laboratories, L.p. | 180 | $70,552 |
| Organon | 69 | $43,506 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 135 | $32,646 |
| Arcutis Biotherapeutics, Inc. | 87 | $29,702 |
| Verrica Pharmaceuticals Inc. | 36 | $26,945 |
| VYNE Pharmaceuticals Inc. | 46 | $26,250 |
| Sun Pharmaceutical Industries Inc. | 119 | $17,112 |
| Dermavant Sciences, Inc. | 65 | $11,701 |
| EPI Health, LLC | 21 | $11,477 |
| LEO Pharma Inc. | 18 | $3,599 |
| Almirall LLC | 20 | $3,068 |
| Mayne Pharma Commercial LLC | 32 | $2,321 |
| Sanofi | 26 | $2,294 |
| Parapro, LLC | 1 | $1,900 |
| Journey Medical Corporation | 13 | $1,791 |
| Eli Lilly | 1 | $1,350 |
| Novartis | 10 | $782 |
| AbbVie | 6 | $393 |
| Regeneron Healthcare Solutions, Inc. | 12 | $372 |
| Pfizer | 21 | $350 |
| UCB, Inc. | 6 | $298 |
| Lilly USA, LLC | 6 | $244 |
| Merz North America, Inc. | 5 | $147 |
| Revance Therapeutics, Inc. | 1 | $143 |
| Stemline Therapeutics Inc. | 1 | $127 |
| E.r. Squibb & Sons, L.L.C. | 4 | $121 |
| Biofrontera Inc. | 2 | $119 |
| Amgen | 3 | $101 |
| Sebela Pharmaceuticals Inc. | 6 | $98 |
| Boehringer Ingelheim | 4 | $87 |
| Botanix SB Inc | 3 | $68 |
| LNHC, Inc | 2 | $40 |
| Kerecis Limited | 1 | $34 |
| Merck | 1 | $17 |
| Mission Pharmacal Company | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$414,705 in reported general payments places this provider in the 95th percentile of 2,031 medical providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ketoconazole | 98 | $1,716 |
| Clobetasol Propionate | 27 | $1,424 |
| Triamcinolone Acetonide | 63 | $466 |
| Metronidazole | 11 | $451 |
| ValacyclovirValacyclovir Hcl | 28 | $397 |
| Doxycycline Hyclate | 23 | $388 |
| Mupirocin | 28 | $202 |
Paid to pharmacies, not to this prescriber.
Other medical in Naples
- Yekaterina GrigolNaples$18K
- Gary RubinRockledge$2.1M
- Krystie LennoxBoca Raton$245K
- Jihan RamadanWellington$238K
- Ilanit SamuelsMiami$211K
- Erin DouceyWinter Haven$202K
- Kathleen TrummerWellington$166K
- Sandra SnyderTampa$156K
- Francine PhillipsLand O Lakes$145K
- Chelsie FerrellDeland$132K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.